United Therapeutics (NASDAQ:UTHR) CEO Sells $4,863,715.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $511.97, for a total transaction of $4,863,715.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $166,105,082.71. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Stock Performance

Shares of UTHR traded up $5.58 during trading hours on Tuesday, reaching $518.46. The stock had a trading volume of 875,723 shares, compared to its average volume of 492,121. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35. The stock has a market capitalization of $22.24 billion, a PE ratio of 18.55, a PEG ratio of 1.74 and a beta of 0.59. The company’s 50-day moving average is $532.35 and its two-hundred day moving average is $538.04.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.41 EPS. Equities analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Institutional Trading of United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. California State Teachers Retirement System lifted its position in shares of United Therapeutics by 55,526.2% in the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after purchasing an additional 33,229,108 shares during the period. BlackRock Inc. acquired a new stake in shares of United Therapeutics during the second quarter worth $2,868,735,000. Avoro Capital Advisors LLC raised its stake in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Wellington Management Group LLP lifted its holdings in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the period. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.